



Media Release

23 April 2013

PHARMAXIS INVESTOR CONFERENCE CALL

Pharmaxis Ltd (PXS) expects to complete its analysis and announce the results of its Phase III clinical trial of Bronchitol in patients with bronchiectasis prior to opening of the market tomorrow, 24 April 2013. That announcement will have the effect of lifting the current trading halt over the company's shares.

The company will hold an investor teleconference at 9.30am tomorrow after release of the announcement to discuss the results.

Telephone access (toll free):

- Australia: 1800 059 809 or 1800 606 599
- USA/Canada: 1855 881 1339
- UK: 0800 051 8245
- NZ: 0800 453 055

Telephone access (metered): +61 2 9008 9005

Online access details are available on the Pharmaxis website home page at www.pharmaxis.com.au

A recording of the conference will be available on the Pharmaxis website home page approximately 3 hours after the call.

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Pharmaxis Investor Relations

T: +61 2 9454 7200, F: +61 2 9451 3622,

E: Investor.Relations@Pharmaxis.com.au Website: www.pharmaxis.com.au